Analytical Data
-
Gene name
PI15
- Application
-
Alternative Names
PI15；CRISP8；P25TI；Peptidase inhibitor 15
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O43692
-
Expression Region
61-258aa
-
AA Sequence
YISQNDMIAI LDYHNQVRGK VFPPAANMEY MVWDENLAKS AEAWAATCIW DHGPSYLLRF LGQNLSVRTG RYRSILQLVK PWYDEVKDYA FPYPQDCNPR CPMRCFGPMC THYTQMVWAT SNRIGCAIHT CQNMNVWGSV WRRAVYLVCN YAPKGNWIGE APYKVGVPCS SCPPSYGGSC TDNLCFPGVT SNYLYWFK
-
Molecular Weight
29 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PI15, or PAI-1 (Plasminogen Activator Inhibitor-1) protein, is an important regulatory component in the fibrinolytic pathway, which is responsible for the breakdown of blood clots. Elevated levels of PI15 have been linked to various pathological conditions, including cardiovascular diseases, obesity, and certain types of cancer, due to its role in inhibiting tissue plasminogen activator and urokinase plasminogen activator. Researchers have shown interest in PI15 for its potential as a biomarker for disease progression and as a therapeutic target. Studies have indicated that modulating PI15 levels could influence clotting dynamics and tissue remodeling processes, making it a candidate for drug development. Furthermore, understanding the mechanisms regulating PI15 expression may offer insights into the pathophysiology of thrombotic disorders. Advances in recombinant protein technology have facilitated the production of PI15 for in vitro and in vivo studies, allowing for a deeper exploration of its functions and interactions within the circulatory system. Ongoing research aims to clarify the molecular pathways involving PI15 and identify how it can be effectively targeted to improve clinical outcomes in conditions characterized by abnormal fibrinolytic activity.
